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Abstract
Background: Data on long-term prognosis of metastatic GCT (mGCT) is scant. The frequency of
spontaneous regressions (SRs) is unknown. We aimed to estimate the prognosis of mGCT.
Methods: We searched electronic scientific literature databases and generic Internet from January
1980 to August 2017. After identifying eligible studies we performed descriptive analyses and
meta-analyses to estimate overall survival (OS), disease specific survival (DSS) and frequency of
SRs in the years before the widespread use of denosumab. We performed pre-specified subgroup
analyses of studies published before and after 2000 and of those with more and less than 10 years
of follow-up.
Results: After retrieving and combining data from 26 relevant retrospective case-series totaling
242 patients with a median follow-up of 6.9 years, the estimated pooled OS was 86.9% (95% CI
78.0–94.2). Pooled DSS was 88.0% (95% CI 79.7–94.7). SRs were observed in 4.5% of patients. In
the subgroup of studies published after 2000 mGCT was the only cause of death of affected sub-
jects. In case-series with a follow-up longer than 10 years pooled DSS was 69.7% (95% CI
25.5–99.8).
Conclusions: To our knowledge this is the first study to derive estimated pooled OS and DSS of
mGCT based on a large dataset. SRs were not exceptional phenomena. In a long run the disease
could impact in a significant way on the life expectancy of affected subjects.
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Introduction
Giant cell tumor of bone (GCT) is a benign neoplasia prone to an
aggressive local behavior and, to a lesser extent, to metastasize (1,2).
It represents 4–8% of all primary bone tumors in USA and Europe
(3). Higher figures have been reported in Asian populations, up to
14% in China and up to 30% in Southern India (4). Estimating of
the incidence of GCT is challenging, because few population-based
cancer registries record benign bone tumors (5). Its incidence was
1.3 per million people per year in a population-based registry in
Sweden (3). It originates in a mature bone tissue, and thus, more
than a half of the cases is diagnosed between the third and fifth dec-
ade of life (4).
GCT is composed by three main cellular subtypes: fusiform stro-
mal cells (SC), osteoclast-like giant multinucleated cells (GMC) and
macrophage-like round mononuclear cells (RMC). The SC is the
main component of neoplasia, responsible for its proliferative
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capacity. Their biological properties are those of the osteoblastic
linage cell. They express the ligand of receptor activator nuclear
factor kappa-B (RANK-L) in their surface (6). The GMC exhibit
osteoclast-like phenotypic features and have the bone resorption as
their main function (1,2,7–9). The GMC are formed as a result of
RMC fusion. The recruitment of RMC, their fusion, and the activity
of GMC is dependent on numerous chemotactic factors derived
from SC (1,2,7–13).
The biological behavior and clinical course of the disease are
both difficult to predict: 18–50% relapse locally after surgical resec-
tion, and 2–3% metastasize systemically, mainly to lung (11,12,14).
Pulmonary metastases (MTS) are histologically benign, and malig-
nant transformation occurs in less than 1% of cases (15). Most of
them are metachronic and only 6–23% are synchronic (16,17).
Time to systemic relapse varies greatly from a few months to more
than 10 years, averaging 1.5–5 years in large case-series (4,17–20).
The data on long-term prognosis of metastatic GCT (mGCT) are
mainly limited to small retrospective studies. The largest of them,
recently published by Yang et al., found a 94.4% 5-year survival
rate based on data from 42 patients (21).
Recommendations for the management of mGCT are mostly
based on Phase 2 studies reporting on a mix of localized and meta-
static GCT, small retrospective series and expert opinion, due to the
lack of published randomized, comparative research, as a conse-
quence of the rarity of the condition. Complete resection, when feas-
ible, is the treatment of choice (17,18,22,23). For unresectable MTS,
medical treatment or surveillance are the available options. The
National Comprehensive Cancer Network (NCCN) most recent
guidelines consider denosumab and interferon- alfa as options for
the pharmacological treatment (24). Cytotoxic chemotherapy also
has been used, frequently in combination with other modalities,
mainly surgery (18,20,22,25–28), but its efficacy for benign mGCT
has been scarcely reported, and its role is loosely determined.
While bisphosphonates (BP) actions both upon SC and GMC
(29,30), denosumab, a fully human monoclonal (igG2) antibody
against RANK-L, interferes with SC stimulation of GMC, producing
a marked depletion of GMC, partial maturation toward the osteo-
blastic phenotype and osteoid formation (31–33).
Treatment with BP has shown to be effective in the adjuvant set-
ting (34) with fewer data in mGCT, but significant tumor size reduc-
tion seems not to be a rule (35). Several published Phase 2 clinical
trials using denosumab enrolled patients with mostly unresectable or
unsuitable for resection GCT, with a variable proportion (near
20%) of patients with lung MTS (33,36–38). Although all showed
very high response and disease control rates, none of them provided
data on patients with lung MTS separately. The follow-up was short
in all but one (37). In this study that reported on 54 patients treated
with denosumab for a median of 54 months with no progression, 14
had MTS (37). However, 6% of treated patients had osteonecrosis
of the jaw and 4% atypical femoral fractures as adverse effects, lim-
iting the duration of the treatment (37). After denosumab discon-
tinuation, 4 out of 10 patients experienced progression of disease
(37). Similar rates of reduced compliance and tumor re-growth after
the denosumab withdrawal was seen in a study from Norway (39).
On the other hand, an indolent course with a 100% survival was
reported even without treatment (28,40,41). Moreover, cases of
spontaneous regressions (SRs) of lung MTS have repeatedly been
published in the literature (16–18,20,22,42,43), but its frequency
has been never determined. To our knowledge, no estimations of
the prognosis of mGCT based on a large, representative sample with
a long follow-up period have been published to date. These
uncertainties could difficult the appraisal of the efficacy of treat-
ments in non-comparative studies. In the absence of published ran-
domized trials, pooled estimates with a better precision derived from
meta-analyses could be useful in clinical practice. We aimed to esti-
mate the overall survival (OS), disease specific survival (DSS) and
SRs rate of mGCT, and depict whether there are some particular
clinical and radiological features associated with this phenomenon.
Methods
We performed a systematic review and a meta-analysis following
the Preferred Reporting Items for Systematic Reviews and Meta-
Analysis (PRISMA) statement (44), and the AMSTAR 2 guidance
document (45).
All authors approved the study protocol prior to start. We
searched Medline, EMBASE, LILACS and the Cochrane Library,
from 1 January 1980 to 30 August 2017. Also, a generic Internet
search was done. Reference lists of included documents were also
hand-searched, as well as their related articles in PubMed and Scholar
Google. Medline search terms included ‘Giant Cell Tumor of
Bone’[Mesh], ‘Neoplasm Metastasis’[Mesh], ‘Fatal outcome’ [Mesh],
‘Survival’[Mesh], ‘Denosumab’ [Mesh], ‘Spontaneous regression’.
Their combination into search strategies utilized with their yield is
shown in Table A1.
We included journal articles and meeting’s abstracts reporting
on clinical studies of any design, describing at least four patients
(less were considered a case reports) with benign mGCT, published
between 1980 and 2017, in English, Spanish, Portuguese and
Russian languages. Reliance on either histopathological examination
or imaging studies for the diagnosis of MTS was allowed.
In order to reduce bias we decided to limit our analysis to the
pre-denosumab era, excluding studies in which denosumab was
used. This drug, in the indirect comparisons, seems to be a more
potent inhibitor of RANK/RANKL pathway than BP (30). Thus,
while on-treatment, it could potentially improve the course of
mGCT in a significant way, leading to selection bias in pooled ana-
lysis due to the inclusion of a mixture of subjects with unequal inter-
ventions. On the other hand, unlike zolendronic acid, in preclinical
models denosumab fails to reduce SC viability (46,47) in line with
the observation of SC persistence in spite of denosumab exposure
and tumor re-growth after treatment cessation (37,39,48,49). In a
very long run, with large periods of denosumab off, it might lead to
the loosing of the initial advantage and even the appearance of a
bias in the opposite direction. Apart from the aforementioned rea-
sons for its exclusion, we found no study describing the prognosis of
denosumab treated patients separately from the results observed in
patients treated with other options in the same study, in order to
perform subgroup analyses.
Other exclusion criteria were malignant GCT and the lack of
data on disease status at the end of follow-up. When there was a
suspicion that two case-series were sharing the same patients, we
kept the one with a better methodological quality, and/or a larger
size and/or a longer follow-up, as judged by the whole team of
investigators in consensus.
Two rounds of article screenings were done, one with titles and
abstracts, and the other with the full-texts of potentially eligible articles,
each one of them done by pairs of authors according to pre-specified
criteria. Data from included articles were extracted by two reviewers
and, in the case of disagreements, group consensus was reached.
Whenever deemed necessary, authors of articles were contacted by
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e-mail for additional information. We extracted data on clinical charac-
teristic of patients, follow-up length, treatment modalities and disease
status at the end of follow-up. The follow-up period was defined as
time elapsed from MTS diagnosis to the end of follow-up. Deaths due
to treatment complications were considered as death from disease.
For the risk of bias assessment of the retrospective studies the
ROBINS-I checklist was used (50). The assessment of publication
bias was performed with Stats Direct, version 2.7.2.
We pooled data from included studies to estimate overall survival
(OS), disease specific survival (DSS), non-related death rate (NRD),
absence of disease at the end of follow-up (NED) and SR rate. DSS
denotes cause-specific survival, considering for its calculation only
deaths from the disease and discarding all other causes of death.
Student’s t-test for unknown variance was done at alpha level of
0.05. We conducted fixed and random effects proportion meta-
analyses, using STATA 14.0 (StataCorp LP, College Station, TX,
USA), since no individual prospective information on censoring was
available due to the fact that all studies were retrospective case-series
in nature. For the fixed effects model, we used the inverse of the
generic variance method (51,52). We used the Freeman–Tukey vari-
ant of the arc-sine square-root of transformed proportions method to
stabilize the variance of proportions. We applied DerSimonian–Laird
weights for the random-effects model where heterogeneity between
studies was found. We calculated the I2 statistic as a measure of the
proportion of the overall variation attributable to between-study het-
erogeneity. We performed two separate pre-specified subgroup ana-
lyses comparing studies published before and after 2000 and studies
with follow-up greater and lesser than 10 years. The cut-off points
were chosen under the presumption that they may reflect actual
changes in disease management. A meta-regression analysis was done
to explore the association between length of follow-up and DSS. To
establish if there was an association between CR and DSS a univari-
ate robust lineal regression model was used. Additionally we per-
formed post-hoc analyses using individual patients data (IPD), when
available, to explore associations between time from primary to sys-
temic metastases, complete resection, and presence of local recurrence
with the probability to stay alive at the end of follow-up expressed as
a binary outcome.
Table 1. Metastatic GCT – data on survival and spontaneous regression rate
Author Year N Years of
follow-up








Rock et al 84 8 5.4 2/8 (25.0) 0 2 (25.0) 6/8 (75.0) 0 59
Bertoni et al. 85 7 5.7 1/7 (14.3) 0/7 (0) 4/7 (57.1) 6/7 (85.7) 0 56
Bertoni et al. 88 6 4.6 0/6 0/0 6/6 (100) 6/6 (100) 2 57
Tubbs et al. 92 13 10.7 3/13 (23.1) 2/13 (15.4) ND 8/13(61.5) 1 17
Kay et al. 93 6 7.5 1/6 (16.7) 0/6 (0) 3/6 (50.0) 5/6 (83.3) 1 22
Lausten et al. 96 5 13.1 5/5 (100)f 0/5 (0) 0/5 (0) 0/5 (0) 0 60
Cheng et al. 97 4 12.6c 0/4 (0) 0/4(0) 2/4 (50.0) 4/4 (100) 0 61
Osaka et al. 97 6 8.7 2/6 (33) 0/6 (0) 1/6 (16.7) 4/6 (66.7) 1 26
Siebenrock et al. 98 23 7.9 5/23 (21.7) 3/23 (13.0) 13/23 (56.5) 15/23(65.2) 1 18
Takanami et al. 98 4 4.9 0/4 (0) 0/4 (0) 4/4 (100) 4/4 (100) 0 23
Faisham et al. 04 6 2.0b 1/6 (7, 16) 0/6 (0) 2/6 (33.3) 5/6(83.3) 0 62
Dominkus et al. 06 14 6,3 0/14 (0) 0/14 (0) 10/14 (71.4) 14/14(100) 0 58
Donthineni et al. 08d 7 6.0 2/7 (28.6)f 0/7 (0) 2/7 (28.6) 5/7 (71.4) 2 27
Balke et al. 08 7 4.6 1/7 (14.3) 0/7 (0) 1/7 (14.3) 6/7 (85.7) 0 25
Klenke et al. 10 7 ND 1/7 (14.3) 0/7 (0) 3/7 (42.9) 6/7 (85.7) 0 41
Viswanathan et al. 10 24 1.9 0/21 (0) 0/24 (0) ND 24/24(100) 0 28
Errani et al. 10 14 ND 0/14 (0) 0/14 (0) 3/14 (21.4) 14/14(100) 0 40
Takeuchi et al. 11 8 2.3 0/8 (0) 0/8 (0) 3/8 (37.5) 8/8 (100) 0 63
Kremen et al. 12 5 ND 0/5 (0) 0/5 (0) 1/5 (20.0) 5/5 (100) 1e 68
Niu et al. 12 21 6.3 3/21(14.3) 0/21 (0) 0/21(0) 18/21 (85.7) 0 4
Boriani et al. 12 6 7.8 2/6 (33.3) 0/6 (0) 4/6 (66.7) 4/6 (66.7) 0 64
Jiang et al. 13 11 ND 1/11 (9.0) ND ND 10/11 0 65
Xing et al. 13 6 5.0 2/6 (33.3) 0/13 ND 4/6 (66.7) 0 66
Liu et al. 13 5 5.1 0/5 (0) 0/5 (0) 1/5 (20.0) 5/5 (100) 1e 42
Chen et al. 16 7 9.2 2/7 (28.6) 0/7 (0) 5/7 (71.4) 5/7(71.4) 1 20
Kito et al. 17 12 13.3 1/12 (8.3) 0/12 (0) 4/12 (33.3) 11/12 (91.7) 0 19
Mean (95% CI) 9.3 (6.9–11.7) 6.9 (3.5–10.2) 2.2 4.5
Median (IQR) 7.0 (6.0–11.7) 6.2 (4.9–8.5) 14.3 (0–24.5) 0 40.2 (20.4–57.0) 85.7 (71.4–100)
Range 4–24 1.9–13.3 0–100 0–15.4 0–100 0–100
Data available 205 242 231 188 242 242
Total 242 35 5 76 202 11
DOD, death of disease or its treatment; NRD, non-related deaths; NED, no evidence of disease; CI, confidence interval; IQR, interquartile range.
aComplete and partial regressions.
bThe follow-up of two out of six patients was reported.
cFrom this case-series of five patients the data of four treated surgically available in the abstract was included, due to the impossibility to access the full-text.
dOnly spine GCT.
ePartial regression.
fOne patient died from sarcomatous transformation of lung metastasis.
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Further we described nine cases of SR retrieved through an add-
itional non-systematic database and Internet generic search to deter-
mine if there exist some clinical o radiological peculiarities associated
with a SR of MTS.
Results
The search in electronic databases and a generic Internet retrieved a
total of 2095 citations. After removing duplicates and performing
the screening by title and abstract, 116 documents remained. After
the second round of screening by full-text 36 articles were con-
sidered (4,17–23,25–28,33,35–38,40–42,53–68). Of them, 10 stud-
ies were excluded after careful full-text examination: two due to the
lack of information on disease status at the end of the follow-up
(54,55), one because it was not clear if it had been reported on
malignant or benign GCT (53), two studies because the sharing of
the same participants with other included studies could not be ruled
out (35,67), and five due to the denosumab use, an exclusion cri-
teria (21,33,36–38) (Appendix, Table A2). The remaining 26
studies were included in qualitative and quantitative syntheses
(4,18–20,22,23,25–28,40–42,56–66,68) (Table 1). The studies
selection process is summarized in the study flow chart (Fig. 1).
Details of the methodological quality assessment of included studies
are shown in the Appendix (Table A3). All were retrospective case-
series, published between 1984 and 2017. Nine studies were from Asia
Pacific Region (4,19,20,23,26,42,63,65,66), two from South Asia (28,62),
four from Europe (25,40,58,60), seven from USA (17,22,41,56,59,61,68)
and four were intercontinental collaborations (27,57,59,64). Sixteen stud-
ies had MTS as their exclusive or main topic (17–20,22,23,26,27,42,56–62),
two studies reported on recurrent GCT, including distant MTS (41,63).
The remaining case-series, although referred to localized GCT, provided
information on patients with systemic relapse. The median number of
patients in a case-series was of 7, interquartile range (IQR) 6–11.7.
Although the majority of studies carried biases inherent to their epi-
demiological design, all provided data on survival status of patients at
the end of follow-up. The information on treatment was lacking in
seven out of 26 studies. The type of data on non-surgical treatments
precluded any analyses of their impact on survival (Table 2). No evi-
dence of publication bias was detected (see Appendix, Fig. A4).
The total number of subjects analyzed was 242. The mean age was
of 29.1, median male to female ratio 1.33. Almost all described MTS
were to lung. Across all studies 14 extrapulmonary MTS were identi-
fied: to muscle, bone, scalp, lymph nodes, heart, tongue, chest, small
intestine and brain (4,28,35,59,60,64). Median of patients with patho-
logically verified MTS was 70% (IQR: 35–100%). Data on the elapsed
time from primary tumor to systemic MTS (TTM) was available in 202
subjects. Mean TTM was 2.4 years. In 64% of patients with systemic
MTS a local relapse also occurred. Treatment modalities used were: sur-
gical removal (complete or incomplete, including ‘re-resections’), chemo-
therapy (CT), BP, biological therapy, radiotherapy, observation and
Figure 1. Flow diagram of study selection.
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their combinations (Table 2). The mean follow-up was 6.9 (range
1.9–13.3) years (Table 1).
For all 26 studies considered together, the estimated pooled OS was
86.9% (95% CI: 78.0–94.2), with an I2 test for heterogeneity of 58.7
(Fig. 2A). Pooled DSS was 88.0% (95% CI: 79.7–94.7%), I2 = 53.7%
in a random effects model (Fig. 2B). Under a fixed effects model very
similar results were obtained (see Supplemental digital content S1).
When the 22 case-series with available follow-up time were taken into
account, the pooled OS and DSS were similar, 84.6% (95% CI:
74.0–93.3) and 85.8% (95% CI: 75.9–93.9) respectively (Fig. 2C, D).
Overall, 40 (16.5%) out of 242 subjects died, 35 (14.5%) from
the disease or treatment complications and five (2.1%) from non-
related causes (Table 1). Four out of 242 (1.7%) patients died from
CT toxicity, three in the older studies and one in post-2000 sub-
group. Malignant transformation was reported in six out of 242
(2.5%) patients. The information on the presence or absence of
Table 2. Treatment of metastatic GCT in the included case-series
Author Year N OBS CR PR STa MT NA Ref
Rock et al. 84 8 0 6 1 1 CT 5
(CR + CT) (4)
(CT + RT) (1)
0 59
Bertoni et al. 85 7 0 0 0 0 7
(CR + CT) (1)
(PR + CT) (4)
(PR + CT +
BCG) (2)
0 56
Bertoni et al. 88 6 2 3 0 1 RT 0 57
Tubbs et al. 92 13 0 4 8 1 NA 0 17
Kay et al. 93 6 1 3 2 0 (CR + CT) (1) 0 22
Lausten et al. 96 5 – – – – – 5 60
Cheng et al.b 97 4 – – – – – 4 61
Osaka et al. 97 6 0 3 0 3 CT 3
(CR + CT) (1)
(RT + CT) (2)
0 26
Siebenrock et al. 98 23 2 14 2 2 CT 3
(CR + CT) (2)
(RT + CT) (1)
3 18
Takanami et al 98 4 0 4 0 0 0 0 23
Faisham et al. 04 6 2 2 0 2 CT 0 0 62
Dominkus et al. 06 14 0 11 1 2 CT 0 0 58
Donthineni et al. 08 7 0 1 1 5 CT 2
(CR + CT) (1)
(CT + RT)(1)
0 27





alpha or BP or
CT + CR (4)
(CR + RT) (1)
0 25
Klenke et al. 10 7 – – – – – 7c 41
Viswanathan et al. 10 24 10 8 0 4 CT 2 (CR + CT) 2 28
Errani et al. 10 14 – – – – – 14 40
Takeuchi et al. 11 8 5 3 0 0 0 0 63
Kremen et al. 12 5 0 3 0 2 NA 0 0 68
Niu et al. 12 21 0 0 0 5 CT (1)
BP (4)
0 16 4
Boriani et al. 12 6 – – – – – 6 64
Jiang et al. 13 11 – – – – – 11 65
Xing et al. 13 6 – – – – 6
Liu et al. 13 5 0 1 1 3 CT BT’ 0 0 42
Chen et al. 16 7 4 1 0 2 CT 1 (CR + CT) 0 20
Kito et al. 17 12 2 5 4 1 CT 0 0 19
Total N (%) 242 28 (16%) 77 (44%) 20 (11%) 36 (21%) 29 (17%) 67 (38%)
Median 0 41.7 0 14.3 0
Data available 175
A/T, available for analysis/Total; OBS, observation; CR, complete resection with or without other modalities; PR, partial resection; ST, systemic therapy (any)
without surgery; MT, multimodality treatment; NA, not available; CT, chemotherapy; RT, radiation therapy; BT, biological therapy; BP, bisphosphonates
aSystemic Therapy (ST): Any pharmacological treatment.
bFrom this series of five patients the data on four patients treated surgically were included due to the impossibility to access the full-text.
cPatients were subject to surgical treatment, chemotherapy and radiotherapy, but cannot provide more information.
dNot specified.
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Figure 2. Metastatic GCT. Estimated pooled overall and disease specific survival. (A) Overall survival in studies published before and after 2000. (B) Disease spe-
cific survival in studies published before and after 2000. (C) Overall survival in studies with the length of follow-up of more and less than 10 years. (D) Disease
specific survival in studies with a follow-up length more and less than 10 years. Black squares and black lines indicate percentage of survivors in each study
with their respective 95% CIs. The size of red diamonds is proportional to 95% CIs of each subgroup. Red dashed line indicates the estimated pooled survival in
the whole study population. Abbreviations: DSS, disease specific survival.
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disease at the end of follow-up was available in 188 out of 242
(77.7%) patients from 22 studies. The median of patients with NED
was of 40.2%.
SRs were observed in 11 subjects (4.5% of cases); about two-
thirds of them were complete regressions and one-third–partial ones
(data not shown, available on demand).
Figure 2. Continued
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A comparison between studies published before and after 2000 is
shown in Table 3 and Fig. 2A, B. Demographic characteristics were
similar. There was a trend to a longer mean follow-up, 8.1 vs 5.8
years, P = 0.054, higher complete resection rate (CR) 53.9% vs
38.0%, P = 0.20 and higher proportion of patients with NED, 53.3%
vs 32.4%, P = 0.11 in the subgroup of pre-2000 studies. A trend to a
greater proportion of patients on surveillance in the post-2000 subset
21.8%, P = 0.053 was observed. NRD in the pre-2000 cohort was of
6.2%, while no NRD in the post-2000 subgroup was observed.
In the pre-2000 cohort pooled OS and pooled DSS were 75.4%
(95% CI: 56.0–91.3) and 78.2% (95% CI: 59.3–93.2), respectively.
In the post-2000 cohort pooled OS and pooled DSS were both of
Figure 2. Continued
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93.1% (95% CI: 86.0–98.2). In a meta-regression analysis, even
after adjusting for follow-up length, the DSS was better in the post-
2000 period (Fig. 3A).
In an exploratory analysis using a multivariable logistic regres-
sion model, based on individual data of 127 patients, after adjust-
ment by age and gender, a greater interval from primary to
diagnosis of MTS was associated with a greater probability to be
alive at the end of the follow-up, OR 0.84 (95% CI: 0.74–0.96) P =
0.02, while no statistically significant association with neither the
presence of local recurrence nor the achievement of complete resec-
tion was found based on individual data of 116 and 115 subjects,
respectively (data not shown, available on demand).
Figure 2. Continued
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In the subset of studies with a follow-up shorter than 10 years
pooled OS and DSS were 90.3% (95% CI: 83.0–96.1) and 91.1%
(95% CI: 84.3–96.4) respectively. In those followed-up for more
than 10 years pooled OS and DSS were 66.7% (95% CI: 23.2–98.8)
and 69.7% (95% CI: 25.5–99.8) (Fig. 2C, D). In a meta-regression
analysis of DSS adjusting by follow-up time the regression coeffi-
cient was –0.027, P = 0.22 (Fig. 3B).
Finally, we describe nine cases of SRs (Table A4) (16–18,20,22,42,43).
Four of them were retrieved through an additional generic Internet search
(16,43). Time from the lung MTS diagnosis to their regression varied from
1 to 16 years. Most of the regressions were complete. Few articles reported
on the duration of SRs. However, after a spontaneous disappearance no
cases of ‘re-metastasis’ were detected. We failed to identify any particular
clinical feature associated with the SR phenomenon, possibly with excep-
tion of the freedom of primary tumor relapse. We found two case-reports
each one reporting on a patient with multiple radiologically calcified pul-
monary nodules (43,69). After the surgical removal, all of the nodules
exhibited either hyalinosis or ossification without viable tumor (43,69).
Interestingly, a massive calcification of the primary and MTS in patients
treated with denosumab reported by Palmerini et al. kept some similarity
with these cases (37). If true, the radiologic sign of ‘spontaneous’ ossifica-
tion, although infrequent, may, hypothetically, be regarded as an argument
against the surgical resection of lung MTS.
Discussion
The natural history of GCT with pulmonary MTS is extremely vari-
able (23). Published case-series show a very wide spectrum of pos-
sible routes of its evolution which spans from an overt progression
with respiratory failure to a complete long-standing spontaneous
regression, probably equivalent to healing, including in most cases
intermediate situations, like partial spontaneous regressions, long
periods of stability o very slow growth (17,18,20,60,68). Even
though lung MTS are persistent, patients may stay alive for very
many years (70). Our study addressed this uncertainty.
We found that the pooled OS was of 86.9% and the pooled DSS
was of 88.0% at 7 years of follow-up. Equal DSS and OS of 93.1%
in those studies published after 2000 was observed. This means that
mGCT was the only cause of death in that patients and thus, it can-
not be regarded as inoffensive for persons typically aged between 20
and 40.
Although in a meta-regression a trend to inverse relationship
between DSS and follow-up was not statistically significant, in cases-
series with more than 10 years of follow-up DSS was 69.7%, rather
low for a condition considered benign. This decrease of survival rates
was associated with a pronounced widening of the confidence interval
(Fig. 2C, D). This may be interpreted as that although with a longer
follow-up the uncertainty about the mGCT prognosis would increase,
in a very long run the impact on the life expectancy may be greater
than established by us.
Although confidence intervals slightly overlap, there has been a
considerable increase in OS and DSS in the post-2000 series in com-
parison with older ones. It can be hardly attributed to a more
aggressive surgical treatment, as CR and NED rates were not statis-
tically different, and even a trend to an inverse relation was
observed. Likewise, the proportion of patients on surveillance in
post-2000 showed a three-fold increase (P = 0.053). Due to the
exploratory nature of the analyses based on retrospective data this
results should be taken with caution. This increase of DSS and OS
can only partially be explained by the shorter follow-up and the
reduction of CT related deaths in the post-2000 subgroup (Table 3).
The findings reported by Lausten et al., showing 0% survival at 13
years of follow-up, and possibly some unknown factors, may add-
itionally contribute for this apparent DSS improvement. A stage
migration, given to the continuous amelioration of imaging studies
quality, cannot be ruled out, especially since in older case-series
MTS diagnosis was made by plane chest radiographs in some cases
(18). A parallel reduction of NRD observed, attributable to an over-
all life expectancy improvement over time, in addition to a shorter
follow-up, may account for the OS difference (Table 3).
Determination of the impact of chemotherapy on survival based
on retrospective data is usually troublesome and prone to criticism.
With the type of data like ours, the analysis would be further biased
by the diversity of chemotherapy regimens used, variable duration of
therapy, lack of detailed information about chemotherapy in many
studies, use of chemotherapy in combination with other modalities. In
some patients with persistent lung MTS, several years elapsed from
chemo to the end of follow-up, which poses an additional difficulty
when an inference about a cause–effect relation is attempted.
Considered potentially misleading, estimates were not performed.
The main methodological limitation of our work is the retrospect-
ive nature of observational studies, prone to some time-related biases,
such as lead time bias and immortal time bias, and the lack of data
on follow-up length in some studies. Other methodological flaws are
the lack of data on treatment and freedom of disease in some case-
series. Additionally, diagnostic misclassification could have taken
place in some few cases, as histopathological diagnosis was verified
Table 3. Comparison between the case-series of metastatic GCT published before and after 2000
Before 2000 After 2000 P value, one-tailed
Student’s t-test
N of series 10 16
N of patients 82 160
Age. Mean (95% CI) 27.8 (24.1–31.6) 30.5 (28.0–33.0) 0.15
Male: Female. Median (IQR) 1.0 (0.9–2.0) 1.7 (1.3–2.9) 0.33
Follow-up in years. Mean (95% CI) 8.1 (5.9–10.3) 5.8 (3.7–7.9) 0.054
Observation %. Mean (95% CI) 7.3 (6.3–8.3) 21.8 (5.5–38.1) 0.053
Complete resection %. Mean (95% CI) 53.9 (32.0–75.6) 38.0 (21.0–54.1) 0.20
Death rate from disease and its treatment %. Mean (95% CI) 23.4 (2.4–44.4) 10.5 (4.2–16.7) 0.11
Death rate from non-related cause. N (%) 5/82 (6.1) 0/160 (0.0)
NED as % of the total. Mean (95% CI) 53.3 (28.1–78.5) 32.4 (17.9–46.9) 0.09
Spontaneous regression. N (%) 6/82 (7.3%) 5/160 (3.12%)
IQR, Interquartile range; CI, confidence interval, NED, no evidence of disease.
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in only 70% of patients and H3F3A and H3F3B gene mutation ana-
lyses were not performed.
As individual data was available in 122 out of 242 patients (not
shown), we combined the extracted from published literature
aggregated data on survival at a single fixed point in time.
Although this approach was criticized when applied to time to
event continuous outcome, it may be suitable when a binary out-
come is used (71).
The main strength of this study is its comprehensiveness gather-
ing a relatively large number of subjects for a rare condition. The
design and number of participant of selected studies were rather
uniform. To our knowledge, this is the first systematic review on
mGCT published to date and a first meta-analysis attempting to esti-
mate the prognosis of the disease based on a large dataset. Also, this
is the first synthesis of data on SR.
The study addressed the unmet need for a more precise knowl-
edge about the prognosis of mGCT circumscribing reference values
of DSS and SR. Data provided by us can be useful as an historical
control in the assessing of long-term results of mGCT treatment.
As a hypothesis to put forward, we propose to consider mGCT
not like a benign, but rather like a premalignant lesion. In analogous
way to other premalignant lesions it, sometimes, may be multifocal,
Figure 3. Metastatic GCT. Estimated pooled disease specific survival adjusted by the follow-up time. (A) Before and after 2000. (B) Circle size is proportional to
the number of patients in each study. Abbreviations: DSS, disease specific survival.
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persist for large periods, progress to high-grade malignancy or retro-
grade spontaneously. In contrast to typical well-known epithelial pre-
malignancy, which acquire the capacity to uncontrolled proliferation
first and the metastasing capacity later in their evolution, in the case
of mGCT there is an inversion of this order. A reported case of malig-
nant recurrence at the primary site with simultaneous benign multiple
lung MTS provide some empiric support for this hypothesis (72).
We hope that in the future the development of new biomarkers
focused on identification of differential expression of genes, pro-
teins, micro-RNAs and cytogenetic alterations will allow a better
assertion of mGCT prognosis and individualization of the thera-
peutic decision (73–78).
In conclusion, we derived estimated pooled OS and DSS of
mGCT based on a large dataset. SRs were not exceptional phenom-
ena. Metastatic GCT was the only cause of death of patients with
this condition in studies published after 2000. With follow-up great-
er than 10 years a trend to a lower DSS was observed. In a long run
the disease could impact in a significant way on the life expectancy
of affected subjects.
Supplementary data
Supplementary data are available at Japanese Journal of Clinical
Oncology online.
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